Ventriculolumber perfusion of 3-[(4-amino-2-methyl-5-pyrimidinyl)-methyl]-1-(2-chloroethyl-1-nitrosou rea hydrochloride for subarachnoid dissemination of gliomas.
The toxicity and therapeutic effect of the ventriculolumber perfusion of 3-[(4-amino-2-methyl-5-pyrimidinyl)methyl-1-1(2-chloroethyl)-1-nitros our ea hydrochloride (ACNU) against subarachnoid dissemination of gliomas were studied. Twenty-one patients (6 patients with anaplastic glioma, 7 with glioblastoma and 8 with medulloblastoma or PNET) received ventriculolumber perfusion of ACNU when they were diagnosed as having subarachnoid dissemination. The course of perfusion and cumulative dose of ACNU was 10 times and 95 mg on average, respectively. Most of the patients received systemic chemotherapy in combination with perfusion therapy and some patients with radiotherapy. Response rate was 17% and median survival time after the diagnosis of dissemination was 12 months for anaplastic gliomas, 29% and 12 months for glioblastoma, and 88% and over 25 months for medulloblastoma and PNET. The ventriculolumber perfusion of ACNU was performed for prophylactic purpose in 7 patients with high risk at the early postoperative period in combination with conventional adjuvant therapy. The course of perfusion and cumulative dose of ACNU was 2.3 times and 21 mg on average, respectively. One patient developed subarachnoid dissemination and died 22 months after surgery. Other 6 patients survived without dissemination on median over 29 months after surgery. Side effects encountered were headache in 4 patients, nausea and vomiting in 5, a convulsion in 2, right facial weakness in 1, fecal incontinence in 3 and meningitis in 2. They were all temporary except for facial weakness occurred in one patient. These data suggest that the ventriculolumber perfusion of ACNU is a safe and useful in the treatment and prophylaxis against the subarachnoid dissemination of gliomas.
Department of Neurosurgery, Kumamoto University Medical School, Japan.
Y
Y
Ushio
M
M
Kochi
I
I
Kitamura
J
J
Kuratsu
D000293:Adolescent; D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000473:pathology; D002528:Cerebellar Neoplasms / Q000188:drug therapy / Q000473:pathology; D002648:Child; D002675:Child, Preschool; D004806:Ependymoma / Q000188:drug therapy / Q000473:pathology; D005909:Glioblastoma / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D007276:Injections, Intraventricular; D008527:Medulloblastoma / Q000188:drug therapy / Q000473:pathology; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D018242:Neuroectodermal Tumors, Primitive / Q000188:drug therapy / Q000473:pathology; D015376:Nimustine / Q000008:administration & dosage*; D000091402:Prohibitins; D013346:Subarachnoid Space / Q000473:pathology
D000970:Antineoplastic Agents; C000717331:PHB2 protein, human; D000091402:Prohibitins; D015376:Nimustine